TORONTO, Oct. 19, 2017 (GLOBE NEWSWIRE) â€” 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is pleased to announce the addition of Keith Cassidy to the Companyâ€™s board of directors and to the Companyâ€™s audit committee, effective immediately. In addition, 3DS announces the appointment of Jason Flowerday to the Companyâ€™s audit committee and Gordon McCauleyâ€™s appointment as the new Chair of the Audit Committee.
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimerâ€™s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Companyâ€™s website at: http://www.3dsignatures.com.
For further information, please contact:
CEO & Director
Cautionary Note Regarding Forward Looking Statements
This news release contains forward looking statements which constitute â€œforward looking informationâ€ within the meaning of applicable Canadian securities legislation (â€œForward Looking Statementsâ€). All statements included herein, other than statements of historical fact, are Forward Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward Looking Statements. Often, but not always, these Forward Looking Statements can be identified by the use of words such as â€œestimatesâ€, â€œpotentialâ€, â€œopenâ€, â€œfutureâ€, â€œassumesâ€, â€œprojectsâ€, â€œanticipatesâ€, â€œbelievesâ€, â€œmayâ€, â€œcontinuesâ€, â€œexpectsâ€, â€œplansâ€, â€œwillâ€, â€œto beâ€, or statements that events â€œcouldâ€ or â€œshouldâ€ occur or be achieved, and similar expressions, including negative variations.
Such Forward Looking Statements reflect the Companyâ€™s current views with respect to future events are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by 3DS as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many risk factors could cause the Companyâ€™s actual results, performance, achievements, prospects or opportunities to be materially different from any future results, performance or achievements that may be expressed or implied by such Forward Looking Statements, including risks related to risks related to 3DSâ€™ early stage of development; the risk that 3DSâ€™ tests will not be successfully deployed; risks related to 3DSâ€™ dependence on third parties including collaborative partners, licensors and others; risks related to 3DSâ€™ clinical trial recruitment; uncertainties related to 3DSâ€™ clinical trials and test development; that there is currently no market for 3DSâ€™ products and that such market may be slow to develop if at all; risks related to 3DSâ€™ reliance on key personnel; risks related to the competitive nature of the biotechnology industry; risks related to 3DSâ€™ limited operating history, lack of revenue, history of losses and inability to assure that it will earn profits in the future or that profitability will be sustained; risks related to government regulation; risks related to rapid technological change; risks related to the fact that 3DSâ€™ software may now or in the future contain undetected errors, bugs or vulnerabilities; risks associated with 3DSâ€™ international operations; the risk that 3DS or its directors and officers may be subject to a variety of civil or other legal proceedings, with or without merit, including product liability claims; risks related to the protection of 3DSâ€™ intellectual property rights; risks related to 3DSâ€™ limited sales, marketing and distribution experience; risks related to the possibility that 3DSâ€™ directors and officers may be placed in a conflict of interest as a result of their employment or affiliation with third parties, risks related to 3DSâ€™ use and storage of personal information and compliance with applicable privacy laws, as well as those risks discussed under the heading â€œRisk Factorsâ€ in the Companyâ€™s annual information form dated January 31, 2017 and filed on SEDAR. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the Forward Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.
In making the Forward Looking Statements, the Company has made various material assumptions obtaining positive results from 3DSâ€™ current and planned clinical trials; obtaining regulatory approvals with respect to 3DSâ€™ clinical trials which are now ongoing or may in the future be commenced; assumptions regarding general business and economic conditions; 3DSâ€™ ability to successfully develop its tests; 3DSâ€™ current positive relationship with third parties will be maintained; the availability of future financing on reasonable terms; 3DSâ€™ ability to attract and retain skilled staff; assumptions regarding market competition and the products and technology offered by 3DSâ€™ competitors; and 3DSâ€™ ability to protect patents and proprietary rights.
3DS believes that the assumptions and expectations reflected in the Forward Looking Statements in this press release are reasonable, but no assurance can be given that these expectations will prove to be correct. Forward Looking Statements should not be unduly relied upon. This information speaks only as of the date of this press release, and 3DS will not necessarily update this information, unless required to do so by securities laws.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Click here to read the original article.